CLINICAL EVALUATION OF CLARITHROMYCIN, A NEW MACROLIDE ANTIBIOTIC IN CHILDREN

A new oral macrolide, clarithromycin (TE-031, A-56268), was evaluated for its safety, efficacy and pharmacokinetics in 33 children. TE-031 was effective in all cases of mycoplasmal pneumonia, pneumococcal pneumonia, streptococcal pharyngitis, pertussis and Campylobacter gastroenteritis. The pharmaco...

Full description

Saved in:
Bibliographic Details
Published in:Japanese journal of antibiotics 1989/02/25, Vol.42(2), pp.255-262
Main Authors: MEGURO, HIDENORI, ARIMASU, OSAMU, HIRUMA, FUJIAKI, SUGAMATA, KUMIKO, SUGIE, NOBUYUKI, HIGA, AKIKO, SHINOZAKI, TATSUHIKO, ABE, TOSHIAKI, FUJII, RYOCHI
Format: Article
Language:Japanese
Subjects:
Adolescent
Age Factors
Bacteria - drug effects
Bacterial Infections - drug therapy
Bacterial Infections - metabolism
Bacterial Infections - microbiology
Child
Child, Preschool
Clarithromycin
Drug Evaluation
Drug Resistance, Microbial
Erythromycin - analogs & derivatives
Erythromycin - pharmacokinetics
Erythromycin - pharmacology
Erythromycin - therapeutic use
Female
Half-Life
Humans
Infant
Male
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:A new oral macrolide, clarithromycin (TE-031, A-56268), was evaluated for its safety, efficacy and pharmacokinetics in 33 children. TE-031 was effective in all cases of mycoplasmal pneumonia, pneumococcal pneumonia, streptococcal pharyngitis, pertussis and Campylobacter gastroenteritis. The pharmacokinetic availability of TE-031 granule and tablets was much better than the older macrolides; serum half-lives of TE-031 averaged 3.2±0.25 hours (for the granule preparation). No clinical adverse reaction was encountered, but cases of transient mild elevation of the serum GPT (2 cases) and eosinophilia (2 cases) were encountered. From these preliminary data, TE-031 seems to have a place in the treatment of pediatric infectious diseases.
ISSN:0368-2781
2186-5477
DOI:10.11553/antibiotics1968b.42.255